The ALIM chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ALIM chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ALIM stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
View ALIM Detailed Price Forecast - CNN Money | View ALIM Detailed Summary - Google Finance | ||
View ALIM Detailed Summary - Yahoo! Finance | View ALIM Stock Research & Analysis - Zacks.com |
View ALIM Trends & Analysis - Trade-Ideas | View ALIM Major Holders - Barrons | ||
View ALIM Call Transcripts - NASDAQ | View ALIM Breaking News & Analysis - Seeking Alpha | ||
View ALIM Annual Report - CompanySpotlight.com | View ALIM OTC Short Report - OTCShortReport.com | ||
View ALIM Fundamentals - TradeKing | View ALIM SEC Filings - Bar Chart | ||
View Historical Prices for ALIM - The WSJ | View Performance/Total Return for ALIM - Morningstar | ||
View the Analyst Estimates for ALIM - MarketWatch | View the Earnings History for ALIM - CNBC | ||
View the ALIM Earnings - StockMarketWatch | View ALIM Buy or Sell Recommendations - MacroAxis | ||
View the ALIM Bullish Patterns - American Bulls | View ALIM Short Pain Metrics - ShortPainBot.com |
View ALIM Stock Mentions - StockTwits | View ALIM Stock Mentions - PennyStockTweets | ||
View ALIM Stock Mentions - Twitter | View ALIM Investment Forum News - Investor Hub | ||
View ALIM Stock Mentions - Yahoo! Message Board | View ALIM Stock Mentions - Seeking Alpha |
View Insider Transactions for ALIM - SECform4.com | View Insider Transactions for ALIM - Insider Cow | ||
View ALIM Major Holdings Summary - CNBC | View Insider Disclosure for ALIM - OTC Markets | ||
View Insider Transactions for ALIM - Yahoo! Finance | View Institutional Holdings for ALIM - NASDAQ |
View ALIM Stock Insight & Charts - FinViz.com | View ALIM Investment Charts - StockCharts.com | ||
View ALIM Stock Overview & Charts - BarChart | View ALIM User Generated Charts - Trading View |
Alimera Sciences to Report First Quarter 2024 Financial Results on May 14, 2024, and Provide Corporate Update
Posted on Tuesday April 30, 2024
Conference Call to be held the same day at 9:00am Eastern TimeATLANTA, April 30, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will report first quarter financial results on May 14, 2024, prior to the market open. Management will host a conference call at 9:00 AM ET on the sam
Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Posted on Wednesday March 20, 2024
ATLANTA, March 20, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced that, pursuant to Nasdaq Listing Rule 5635(c)(4) and in connection with the appointments of (i) Mr. Todd Wood as President of U.S. Operations of the Company, (ii) Mr. Elliot Maltz as Chief Financial
Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network
Posted on Tuesday March 19, 2024
Protocol AL is studying ILUVIEN or faricimab (6.0 mg) injections versus observation for the prevention of visual acuity loss due to radiation retinopathy ATLANTA, March 19, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that the first patient has been randomized in the DRCR Retina Network’
Alimera Sciences, Inc. (NASDAQ:ALIM) Q4 2023 Earnings Call Transcript
Posted on Friday March 08, 2024
Alimera Sciences, Inc. (NASDAQ:ALIM) Q4 2023 Earnings Call Transcript March 7, 2024 Alimera Sciences, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, thank you for standing by. Good morning and welcome to the Alimera Sciences Fourth […]